Henry Schein recently enhanced its liquidity with a new credit facility equalling $700 million. However, the financial performance of the company's stock has shown variable results, underperforming some days and rising on others. Important updates include
Q2 and Q3 2024 earnings predictions, while major stakeholders like HSBC Holdings and Stifel Financial Corp have raised their holdings. The company has also made strategic moves including entering the
fast-growing dental market in Turkey and reaching an
amended licensing and distribution agreement with BIOLASE. Despite challenges presented in Q1 2024 earnings reports, experts have pointed out both short-term and long-term value potential in
HSIC stocks, while acquisitions, such as the majority interest of TriMed Inc., have been completed. It is also important to note short interest and movements by large stakeholders like VP and President James Breslawski. The stock's performance has had mixed results, with losses on some days and superior performance on others. Finally, HSIC has entered the orthopedic market and recovered from a cybersecurity incident, looking ahead to Q1 earnings.
Henry Schein HSIC News Analytics from Sun, 15 Oct 2023 07:00:00 GMT to Sun, 02 Jun 2024 06:33:23 GMT -
Rating 3
- Innovation 1
- Information 2
- Rumor -2
